JMIR Form Res. 2018 Nov 7;2(2):e24. doi: 10.2196/formative.9935.
The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing.
Lo LL1, Collins IM2, Bressel M3, Butow P4, Emery J5,6, Keogh L7, Weideman P1,8, Steel E7, Hopper JL8, Trainer AH9,10, Mann GB11, Bickerstaffe A8, Antoniou AC12, Cuzick J13, Phillips KA1,8,10.
iPrevent estimates breast cancer (BC) risk and provides tailored risk management information.
The objective of this study was to assess the usability and acceptability of the iPrevent prototype.
Clinicians were eligible for participation in the study if they worked in primary care, breast surgery, or genetics clinics. Female patients aged 18-70 years with no personal cancer history were eligible. Clinicians were first familiarized with iPrevent using hypothetical paper-based cases and then actor scenarios; subsequently, they used iPrevent with their patients. Clinicians and patients completed the System Usability Scale (SUS) and an Acceptability questionnaire 2 weeks after using iPrevent; patients also completed measures of BC worry, anxiety, risk perception, and knowledge pre- and 2 weeks post-iPrevent. Data were summarized using descriptive statistics.
The SUS and Acceptability questionnaires were completed by 19 of 20 clinicians and 37 of 43 patients. Usability was above average (SUS score >68) for 68% (13/19) clinicians and 76% (28/37) patients. The amount of information provided by iPrevent was reported as "about right" by 89% (17/19) clinicians and 89% (33/37) patients and 95% (18/19) and 97% (36/37), respectively, would recommend iPrevent to others, although 53% (10/19) clinicians and 27% (10/37) patients found it too long. Exploratory analyses suggested that iPrevent could improve risk perception, decrease frequency of BC worry, and enhance BC prevention knowledge without changing state anxiety.
The iPrevent prototype demonstrated good usability and acceptability. Because concerns about length could be an implementation barrier, data entry has been abbreviated in the publicly available version of iPrevent.
©Louisa L Lo, Ian M Collins, Mathias Bressel, Phyllis Butow, Jon Emery, Louise Keogh, Prue Weideman, Emma Steel, John L Hopper, Alison H Trainer, Gregory B Mann, Adrian Bickerstaffe, Antonis C Antoniou, Jack Cuzick, Kelly-Anne Phillips. Originally published in JMIR Formative Research (http://formative.jmir.org), 07.11.2018.
BRCA1 gene; BRCA2 gene; breast cancer; clinical decision support; preventive health; risk; screening